Photo Release -- Nasdaq Welcomes Aduro Biotech, Inc. (Nasdaq: ADRO) to The Nasdaq Stock Market
April 15 2015 - 7:11PM
Nasdaq (Nasdaq:NDAQ) announced that trading of Aduro Biotech, Inc.
(Nasdaq:ADRO) commenced on The Nasdaq Stock Market on April 15,
2015.
Aduro is a clinical-stage cancer immuno-oncology company. The
company’s lead candidate – an immunotherapy regimen combining
Aduro’s proprietary CRS-207 with GVAX Pancreas – is in Phase 2b
clinical trials targeting metastatic pancreatic cancer and has
received Breakthrough Therapy designation from the U.S. Food and
Drug Administration.
A photo accompanying this release is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/de5ece9b-f276-4d94-a3b4-f792e593f21f
“Since its founding, Aduro has focused on identifying new and
innovative treatments for cancer,” said Nelson Griggs, Executive
Vice President, Listing Services, Nasdaq. “We are pleased to
welcome Aduro to our family of listed companies and we look forward
to supporting its growth and success in the future.”
By listing with Nasdaq, Aduro joins some of the world’s largest
and most revolutionary healthcare companies. Nasdaq is the exchange
of choice to 94 percent of healthcare companies listed in the U.S.
Markets year to date.
The information contained above is provided for informational
and educational purposes only, and nothing contained herein should
be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Neither Nasdaq nor any
of its affiliates makes any recommendation to buy or sell any
security or any representation about the financial condition of any
company. Statements regarding Nasdaq-listed companies are not
guarantees of future performance. Actual results may differ
materially from those expressed or implied. Past performance is not
indicative of future results. Investors should undertake their own
due diligence and carefully evaluate companies before investing.
ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Aduro Biotech, Inc. (Nasdaq: ADRO)
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company
focused on the development of technology platforms to stimulate an
immune response against cancer. Aduro’s lead platform is based on
proprietary strains of live-attenuated, double-deleted (LADD)
Listeria monocytogenes that induce a potent innate immune response
and have been engineered to express tumor-associated antigens to
induce tumor-specific T cell-mediated immunity. Aduro has received
Breakthrough Therapy designation from the FDA for its lead LADD
regimen, CRS-207 in combination with GVAX Pancreas in pancreatic
cancer. The company is evaluating the proprietary
immuno-oncology combination in the ongoing Phase 2b ECLIPSE
clinical trial and has additional ongoing clinical trials with its
LADD platform in mesothelioma and glioblastoma. The company is also
developing clinical candidates using cyclic-di-nucleotide (CDN)
synthetic small molecule immune modulators that are designed to
activate the intracellular STING receptor, a central mediator of
the innate immune response. For more information, please visit
www.aduro.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic
stock market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,500 listed companies with a market
value of over $9.1 trillion and more than 10,000 corporate clients.
To learn more, visit www.nasdaq.com/ambition or
www.business.nasdaq.com.
The photo is also available via AP PhotoExpress.
NDAQG
MEDIA RELATIONS CONTACT:
Will Briganti
(646) 441-5012
william.briganti@nasdaq.com
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024